Previously, we have shown that ⌬4,16-androstadien-3-one modulates psychological state, reducing negative mood and increasing positive mood (Jacob and McClintock, 2000; Jacob et al., 2001a). In order to determine whether similar musky compounds also produce these effects, we compared the effects of androstadienone to those of androstenol and muscone, measuring the psychological states of 37 participants. Androstenol and muscone were chosen because they too have a musky odor at high concentrations, while androstenol is a steroid like androstadienone and muscone is not. In a controlled laboratory setting, we conducted a double-blind, within-subject, repeated-measures experiment counterbalanced for order of presentation. Under each participant's nose, a nanomolar amount of each compound was presented, masked by clove oil to minimize perceptible olfactory differences. Participants completed a baseline psychological battery and twice again at 25-min intervals after exposure. Androstadienone's effects on psychological state were unique in comparison with those of androstenol and with muscone. Exposure through passive inhalation, rather than dermal contact, was sufficient for these effects. Although this is additional evidence that androstadienone may be a pheromone, it is yet to be determined whether humans exude concentrations into the air adequate for social communication or process this chemical information within natural social contexts. © 2002 Elsevier Science (USA)
Social chemical signals influence physiology, psychological state, and behavior in many animal species (McClintock, 2000 (McClintock, , 2002 . Studying the effects of chemical signals on humans is particularly challenging because human behavior is multiply determined and there are myriad potential chemosignals. These include social odors, both conscious and unconscious, as well as pheromones (McClintock, 2001 ). Responses to these chemosignals can reflect their odor qualities, such as pungency, familiarity, hedonic valance, level of conscious detection, and recognized source of the stimulus. Previously, we have demonstrated that a particular steroid, ⌬4,16-androstadien-3-one (common name: androstadienone), modulates psychological and physiological variables without conscious detection as an odor (Jacob and McClintock, 2000) ; Jacob et al., 2001a) . The goal of this study was to begin evaluating the chemical and olfactory stimulus specificity of androstadienone. Nanomolar amounts of androstadienone affect general emotional and arousal states, quantified by wellvalidated measures of psychological state (POMS, ARCI, and VAS scales; (Jacob and McClintock, 2000) ). Androstadienone prevents the drop in positive mood and rise of negative mood, which typically occur under the odor carrier condition during our experimental protocols. This suggests that androstadienone modulates the physiological mechanisms of emotional states and attention. Indeed, androstadienone alters cerebral glucose utilization in brain areas not typically associated with olfaction, including subcortical regions and widespread areas of the neocortex, including the prefrontal cortex, superior parietal area, and visual cortex (Jacob et al., 2001b) . These widely distributed changes are consistent with modulation of an integrated neural network for regulation of emotional states and attention. The observed effects of androstadienone are not sex-specific, as suggested by others (Monti-Bloch and Grosser, 1991; Monti-Bloch et al., 1994) ; both men and women respond to androstadienone (Jacob and McClintock, 2000a; Jacob et al., 2001a) . Moreover, effects on the autonomic nervous system and mood are seen only in particular social contexts (Jacob et al., 2001a) .
Humans are, to date, the only species other than pigs known to produce significant amounts of androstadienone. Androstadienone has been measured in peripheral plasma of men at 0.01-0.06 g/100 ml unconjugated, 0.05-0.1 g/100 ml sulfate-conjugated (Brooksbank et al., 1969) , 98 ng/100 ml (Brooksbank et al., 1972) , and 2.05 pmol/ml (Fukushima et al., 1991) . It is also found in men's sweat (Labows, 1988) , semen (Kwan et al., 1992) , and axillary hair (Nixon et al., 1988; Rennie et al., 1990) . In women, androstadienone is measurable in plasma at 36 ng/100 ml (Brooksbank et al., 1972) . Fragrance manufacturers claim to have isolated androstadienone from skin cells (Kodis et al., 1998) , although there is no peer-reviewed publication stating how they were extracted, isolated, or identified (Preti and Wysocki, 1999) . Thus there are several sites of androstadienone production that would make it available during human interactions.
Others have reported that androstadienone has unique effects on the surface potentials of the vomeronasal epithelium and speculated that its behavioral effects would also be unique and not generalize to similar compounds (e.g., other 16-androstenes). This apparent stimulus specificity was used to justify calling androstadienone a pheromone. We therefore sought to evaluate the specificity of androstadienone's effect on psychological state. We chose psychological changes as our basis of comparison, deferring any questions or inferences about receptor specificity until we had demonstrated functional effects.
The effects of androstadienone could be associated with its musky odor, detectable at high concentrations, even though at low concentrations it altered psychological state without being consciously detected as an odor. If so, other compounds that have a similar musky odor might produce the same psychological effects.
In the current experiment, we tested this hypothesis by comparing androstadienone with two other musky compounds, the pig pheromone androstenol (5␣-androst-16-en-3␣-ol) and the musk deer pheromone muscone (3-methylcyclopentadecanone or methylexaltone). Androstenol and muscone, like androstadienone, have a musky odor. Androstenol is in the same steroid family of 16-androstenes, while muscone is a 15-carbon ring with a ketone functional group. All three have been used in human perfumes as essential musky ingredients (Engen, 1991) . Such compounds are also stable and effective fixatives used in many different perfumes (Berliner et al., 1991) . Thus, there is the opportunity for generalization of the effects of androstadienone through its common associations with musky odor and common perfumes and fragrance products.
Androstenol is a mating releaser pheromone in the pig (Sus scrofa) and a nonandrogenic 16-androstene steroid like androstadienone. In humans, androstenol and androstadienone are part of the same metabolic pathway in humans (Gower and Ruparelia, 1993) . In addition, adrostenol is also excreted by humans in at least three isomers (Brooksbank and Gower, 1964; Brooksbank, 1970) . Muscone is a territorial releaser pheromone in musk deer (Moschus moschiferus) (Parrott et al., 1985; Agosta, 1992) and is not produced by humans. Both androstadienone and androstenol have been classified prematurely as human pheromones in marketing claims for fragrances and in some basic research (Monti-Bloch and Grosser, 1991; Monti-Bloch et al., 1994) . These claims have been made prior to amassing evidence that they fulfill all of the criteria required to be termed a pheromone in any species (Beauchamp, 1976; reviewed in Jacob et al., 2002; McClintock, 2002) . Whether or not these claims are ultimately substantiated, the effects of androstadienone might generalize to androstenol because they are produced together in humans, but not to muscone, which is a not produced by humans.
We exposed each participant to androstadienone, androstenol, and muscone, masking their musky odor with clove oil, the strong odor used in our previous research (Monti-Bloch and Grosser, 1991; Jacob and McClintock, 2000; Jacob et al., 2001a) . Following the comparison design typically used to compare the effects of similar odorants (Lorig and Schwartz, 1988) , we made independent comparisons of androstadienone with androstenol and with muscone (two repeated-measures within-subjects analyses). An odor comparison design purposely omits "no-odor" carrier conditions, in order to avoid several important confounds. The dramatic difference between the odor conditions and the "control" condition, which obviously has no odor, creates an unconscious "Hawthorne effect." In addition, dramatically different brain states between the no-odor carrier condition and the presence of an odor can produce statistical artifacts (i.e., biasing omnibus F tests) simply as the result of the difference in information between an odorantcontaining condition and a no-odorant condition. This comparison design is also used for clinical treatment trials, in which the gold standard is showing significant differences from "comparable" substances or protocols. Nonetheless, it is important to verify that the effect sizes in this study are comparable to those in studies where there were carrier controls. Therefore, we confirmed that androstadienone in the current study had effects similar in size to those in previous studies (Jacob and McClintock, 2000) .
Finally, in our previous experiments, we had always applied androstadienone directly on the skin under the nose, enabling continuous exposure. This exposure method has always left open the possibility that our observations derived from either direct transcutaneous transmission of the steroid into the bloodstream or the sustained exposure to the steroid remaining on the skin. In this experiment, we determined whether brief passive inhalation of the air space above a small amount androstadienone solution was sufficient to produce its psychological effects. We exposed each subject to the odorants using two methods: (1) simply holding a small amount of the stimulus solution near the nose on a swab for only 4 s and (2) applying the solution to the skin under the nose with a soaked swab, as we had done in our previous studies.
MATERIALS AND METHODS

Participants
Thirty-seven nonsmoking volunteers (18 women and 19 men) participated in a study that we described as investigating a variety of common household odorants, including compounds in perfumes. Participants were blind to our specific hypotheses and the identity of all compounds. The participants were between the ages of 18 and 35 years (means: women, 25.7 years; men, 22.2 years). Participants were students or associated with the medical science community at the University of Chicago. All participants identified themselves as heterosexual and all but 3 were righthanded. Eight women and eleven men described themselves as Caucasian or White, 4 women and 3 men described themselves as African-American, Black, or of African descent, 4 women and 3 men described themselves as of Asian descent, while the rest were of Latin descent or had multiple ethnic backgrounds. This sample represented the ethnic diversity of the community, but did not enable comparisons of ethnic differences. Participants were in good health, with no sinus problems, and no history of any respiratory or reproductive disease. Subjects provided written consent, as required by the Institutional Review Board at the University of Chicago, and were paid for their participation.
Testers and Testing Facility
Two testers (one male age 24 years, of Scottish/ Indian descent, and one female age 22 years, of Filipino descent) ran the data-collection sessions. Testers were assigned randomly to subjects and ran all three sessions of a given subject. The testers were trained to adhere closely to a written script and demonstrated high inter-tester reliability before being approved for data collection by the primary study directors (S.J. and M.M.). The testers wore no strongly scented products during study sessions. We confirmed that there were no significant differences in any of our measures between the two testers (0.32 Յ all P values Յ 0.96 based on analyses of data with tester as a between-subjects variable).
Participants were tested in an isolated testing room (10 ϫ 10 ft in size, 74.3 Ϯ 2°F, with 15 air changes per hour) that was carpeted, with neutral color walls, and well lit with fluorescent light. Two desks were positioned side by side facing the wall to the left of the entrance. Throughout the session the participant sat by the desk farther from the doorway in a comfortable chair.
Stimulus Solutions and Odor Masking
Because we successfully masked awareness of steroid chemosignals in our previous studies using clove oil as a strong-odor olfactory mask (Jacob and McClintock, 2000) , we decided to use clove oil as the olfactory masking component in this experiment as well. The three musky compounds were androstadienone (⌬4,16-androstadien-3-one, Steraloids, Inc.), androstenol (5␣-androst-16-en-3␣-ol, Sigma-Aldrich Co.), and muscone (3-methyl-cyclopentadecalactone, Firmenich). The stimulus solutions were composed of one of the musky compounds at 250 M concentration in a 10% clove oil/90% propylene glycol (by volume) carrier solution. The participants could not discriminate the three solutions as different odors, either in open-ended verbal description or in olfactory characteristics. The subjects described the three solutions as smelling "the same." To further validate our olfactory masking of all three compounds, we asked participants to use Likert scales to describe each solution's intensity (0 to 5), familiarity (0 to 5), and pleasantness (Ϫ5 to 5). There were no significant differences in perception of these olfactory qualities (0.33 Յ all P's Յ 0.97). Moreover, to assess possible trigeminal nerve effects, we asked participants to rate any sensations of itching (0 to 5) or burning (0 to 5). Again, there were no significant differences among all three stimuli in perception of these somatosensory qualities (0.45 Յ all P's Յ 0.55).
Psychological Measures and Testing Procedures
We employed psychological measures that have detected effects of androstadienone exposure in several previous studies (Jacob and McClintock, 2000; Jacob et al., 2001a) . These were the Addiction Research Center Index (ARCI, cf. (Haertzen, 1974a,b) Wit et al., 1990) research. Each VAS is a 100-mm line paired with an adjective. Its ends are labeled "extremely" and "not at all." A subject indicates how much the adjective applies to their state by placing a mark on the line at the appropriate point; Bond VAS items created from the first reported use of VAS measures (Bond and Lader, 1974) . These are the same as the De Wit VAS, but, rather than representing a continuum of intensity for a single adjective, they are marked with antonymic adjectives at either end of the line.
The four psychological measures yielded 62 scores (5 ARCI subscales ϩ 7 POMS subscales ϩ 20 De Wit VAS items ϩ 30 Bond VAS items ϭ 62 total scores). To minimize potential Type I errors from statistically testing each score individually, the data were combined into discrete factor scores. Based on our previous findings (Jacob and McClintock, 2000; Jacob et al., 2001a) , we expected there to be several factors covering positive and negative emotion as well as states of arousal or drug-like euphoria. To confirm these factors in the current study, factor analyses were performed separately on the ARCI/POMS data and on the Lab/Bond VAS data. These two data sets were analyzed independently because they are different types of measures. The ARCI and POMS have well-established subscales (McNair et al., 1971; Haertzen, 1974a,b) . Both the ARCI and the POMS are widely used and validated measures. In contrast, the VAS (Bond and Lader, 1974; de Wit et al., 1990) measures do not have any preestablished subscales.
As expected, factor analyses and varimax rotation confirmed the robustness of previously derived factor structures. Only one of the factors was unique to this study (anxiousness-irritability) and it did not reveal any treatment effects. We confirmed that the factor analysis output corresponded to strongly intercorrelated clusters of questionnaire scores (all linear association and correlation P values less than 0.0001).
A measure for each derived factor was calculated using methods described previously (Jacob and McClintock, 2000) . A factor score for each time interval was obtained by calculating a mean of the measures for each of the factors that had a varimax rotated factor loading Ն0.5. Measures with a negative factor loading were subtracted from the sum of the measures with positive loadings. This sum was then divided by the total number of measures within each factor. The individual factors and measures used to calculate each factor score are listed in Tables 1 and 2 .
Finally, the psychological responses were quantified as a change from their value at baseline, prior to exposure to the olfactory stimuli. A change in factor score from the baseline was calculated for each subsequent time interval and these values were used in analyses. Since the focus of our experiment is on the psychological effects of androstadienone, one repeatedmeasures ANOVA was done in comparison with androstenol and a second in comparison with muscone.
Menstrual Cycle Status
To maximize the ability to discriminate odors, we tested subjects during the periovulatory phase of their menstrual cycle when olfactory sensitivity is highest (Doty, 1981) . Menstrual cycle information was gathered by all 18 women for two consecutive cycle months based on dates of menses onset. The 18 women also collected detailed daily basal body temperature, vaginal secretions, menses, and urinary LH data. Basal body temperature was measured before getting out of bed in the morning. Vaginal secretions and LH measures were collected at 6 PM in the evening to maximize detection of LH rise (Stern and McClintock, 1996) . During the first cycle month, we determined the day when their preovulatory LH surge began (LH surge onset) using a commercially available kit (OvuQuik) and used this information to schedule the testing during the subsequent cycle (Stern and McClintock, 1996) . The testing sessions were scheduled during the late follicular/periovulatory phase of the menstrual cycle (i.e., within a few days of LH surge onset).
Design and Procedures
We used a within-subjects, double-blind design that was randomized for order of exposure to the three stimulus solutions. Participants were asked to come to our human subject room for three sessions, scheduling 1 day between sessions. With the exception of the stimulus solutions, sessions were identical in procedure, environment, time of day (Ϯ1 h), and experimenter interaction. Each participant was tested with the same tester for each of the three sessions. Which tester ran a subject's sessions was determined on the basis of availability. We confirmed that this resulted in random assignment of participants to each of the two testers.
One half hour before each scheduled session, odorants were aliquotted by a laboratory member not involved in the study. Six standard 1.5-ml polypropylene, flat top microcentrifuge tubes were used in a session. These have a surface area less than 5 mm in diameter. All tubes were labeled by colored tape, identifying them according to when in the session they were to be used. Two tubes were empty for practicing/demonstrating the passive inhalation exposure procedure, two tubes contained 50 l of the solution for the passive inhalation, and two tubes contained 130 l of the odorant for epidermal application. The six tubes were placed on a rack outside the human subject room.
Each session followed the same protocol. When participants arrived for a session, they first washed their hands with the nonodorous liquid soap. They were then seated in the human subject room approximately 1.25 m to the right of the tester, who gave them introductory instructions. Participants were asked to limit movement and talking throughout the session, but were free to make observations specific to the sessions.
The sessions were exactly timed and were divided into three intervals: baseline, passive inhalation (nonepidermal application), and epidermal application. In the baseline interval, the participants were administered a baseline battery of psychological state questionnaires presented on a computer screen. If the participants completed the tests before the predetermined end of the baseline interval, the tester provided them with light nonstimulating reading material.
After 30 min, the passive inhalation exposure procedure was demonstrated to reduce its novelty and increase awareness and expectations. Using the empty tubes, each of two cotton swabs, one to be held under each nostril, was dipped into its own microcentrifuge tube for 3 s. Each swab was then held approximately 0.5 in. underneath the nostril for 4 s. This baseline presentation contained no odorant and the subjects were asked to continue breathing normally. The participants were then asked a series of questions about what they smelled.
After a minute, the same exposure procedure was repeated but with swabs dipped into tubes with 50 l of the test solution assigned for that session and held just under each nostril. The participants were again asked to breathe normally without sniffing, resulting in passive inhalation of the stimulus solution. They were then given the second battery of questionnaires.
Twenty-five minutes after the initial exposure, the participants were exposed again, except that the two swabs were dipped into microcentrifuge tubes with 130 l of solution and then swiped twice on the upper lip below the nose, once with each side of the swab head. The participants continued to breathe normally and were then given the same battery of psychological tests. After each application, the tester placed the used cotton swabs and closed microcentrifuge tubes in a sealed plastic bag to prevent any additional ambient exposure. The entire session lasted approximately 90 min.
RESULTS
Main Effects of Treatment Condition
Although participants could not identify any olfactory differences between the three masked com- Note. Chart of items from the Visual Analog Scale (VAS) questionnaire items grouped by factor membership. Items listed with a slash (/) between them are ends of bipolar VAS items. Single descriptor items are from VAS items which rated a single adjective from "not at all" to "extremely." Factors were identified based on scree plot inspection. Items within each factor were included given a varimax rotated factor loading Ն0.5 without rounding.
Eigenvalue:
pounds, androstadienone had unique effects on positive and negative moods as well as mental acuity (see Fig. 1a for androstadienone vs androstenol effects and Fig. 1b for androstadienone vs muscone) . The magnitude of the effect of androstadienone was consistent with that in our previous studies, i.e., it prevented the drop in positive mood observed during the androstenol and muscone conditions, which was the same as the drop seen during exposure to the odor carrier alone (Jacob and McClintock, 2000) . In this study, androstadienone prevented the drop in elation-vigor that did occur in the presence of androstenol (main effect of treatment, F(1, 35) ϭ 6.6, P Յ 0.01) and muscone (main effect of treatment, F(1, 35) ϭ 10.4, P Յ 0.003). This change mirrors the changes in the POMS Positive Mood measure observed in earlier work and was a virtually identical effect size (Jacob and McClintock, 2000 ; a minimal drop in the androstadienone condition vs a 0.35 standard unit drop in the odor carrier condition). Similarly, androstadienone prevented the rise in clearheaded-lucid factor that occurred in the presence of androstenol (main effect of treatment, F(1, 35) ϭ 5.0, P Յ 0.03) and muscone (main effect of treatment, F(1, 35) ϭ 4.3, P Յ 0.04). Again, this was an effect size similar to those of previous studies.
Androstadienone also affected negative mood. Androstadienone prevented the increase in negative-confusion that occurred during exposure to muscone (main effect of treatment, F(1, 35) ϭ 6.2, P Յ 0.02), although its effects were not significantly different from those of androstenol (F (1, 35) ϭ 0.84, P Յ 0.37). This effect was specific to negative-confusion, as androstadienone had no effect on anxious-irritability (main effect of treatment, androstenol, F(1, 36) ϭ 0.03, and P Յ 0.85; muscone, F(1, 36) ϭ 0.58, P Յ 0.45).
Effect of Exposure Methods
Passive inhalation and dermal application had indistinguishable effects on mood, indicating that direct skin contact and prolonged exposure are not necessary for the psychological effects of androstadienone. Moreover, exposure method did not interact with treatment in any of the factors. This occurred when male and female subjects were combined in a single analysis, both with and without a sex of subject interaction term, and when males and female were analyzed separately (0.0003 Յ all F's Յ 3.32; .077 Յ all P's Յ 0.99).
Effect of Sex of Subject
Independent of treatment, the sex of the subject was significant in only one analysis. When androstadienone and muscone data were analyzed together (i.e., when androstenol data were excluded), male subjects reported a greater average increase in Anxious irritability during our study than did the female subjects (F(1, 36) ϭ 6.13, P Յ 0.02). As a result, we included sex of subject as a potential interaction factor in our analyses of treatment effect. However, there were no significant sex differences in response to the compounds for any measure (0.04 Յ all Fs Յ 1.55, 0.22 Յ all P values Յ 0.85).
DISCUSSION
Androstadienone had unique effects on the participants' mood in comparison with androstenol and muscone, even though they could not distinguish any of the compounds as an odor. It prevented both the drop in positive mood and the rise in the negative mood that has previously occurred with our experimental protocol (Jacob and McClintock, 2000) . These results on mood correspond in both type and effect size with our previous findings that compared androstadienone in its strong clove-scented carrier to its carrier alone. Androstadienone also had unique effects on mental acuity in this study. It should be noted, however, that our previous studies have not consistently identified similar factors measuring mental acuity, arousal, or alertness, nor has androstadienone had consistently significant effects on this aspect of psychological function (Jacob and McClintock, 2000; Jacob et al., 2001a) .
During sustained exposure, androstadienone has localized but widely distributed cerebral effects in areas associated with emotion and attention (Jacob et al., 2001b) . The degree to which these effects were distributed throughout the brain suggests that the neural effects of androstadienone cannot be conceptualized strictly in terms of olfactory perception and categorization. The current findings provide additional evidence that androstadienone is a chemosensory stimulus categorically distinct from simple odorants, with psychologically unique effects on humans different from those of two other musky compounds, similar in odor at high concentrations and use in common perfumes and fragrances. It is noteworthy that the effects of androstadienone did not generalize to another 16-androstene, which is similar in structure and also found in a variety of human secretions. The psychological effects did not require direct epidermal application (Jacob and McClintock, 2000) or presentation at the opening of the vomeronasal organ (Monti-Bloch and Grosser, 1991) . Airborne presentation of nanomolar amount during passive inhalation was sufficient. In addition, we found no evidence that androstadienone has exclusive effects on women, as suggested by others (Berliner et al., 1991; Monti-Bloch and Grosser, 1991; Monti-Bloch et al., 1994) . This negative finding is consistent with our previous studies comparing androstadienone with the odor carrier alone (Jacob and McClintock, 2000) . Estratetraenol, which has psychological effects similar to androstadienone (Jacob and McClintock, 2000) , may well show similar stimulus specificity in comparison to androstenol and muscone.
Given the current findings and previous work, androstadienone is clearly a human social chemosignal. Others have claimed that it is a pheromone (Berliner et al., 1991; Monti-Bloch and Grosser, 1991; Monti-Bloch et al., 1994) . We believe this claim to be premature without directly testing each of the various criteria that a compound must meet to be called a mammalian pheromone (reviewed by (Beauchamp et al., 1976; Jacob et al., 2002) ).
The current study is the first to test the criterion that androstadienone has specific effects that are unique in comparison with similar compounds, not just different from the carrier solution (a criterion set forth by Beauchamp, 1976) . Indeed, androstadienone's effects were unique in comparison with two similar compounds, even though they were chemically similar (androstenol) or had similar musky odors at high concentrations (muscone and androstenol).
An additional criterion is that animal pheromones operate independently of their odor properties (criterion set forth by Beauchamp et al., 1976; McClintock, 2000) . Although it is true that some people are able to detect androstadienone at higher concentrations as an odor, in this study and in all previous studies, androstadienone produced its effects without being detected as an odor.
Androstenol and muscone are both animal pheromones and did not have effects on humans comparable to those of androstadienone. This observation is important for evaluating previous claims that androstenol is a human as well as a pig pheromone. However, although species-specificity has traditionally been a criterion for classifying a compound as a pheromone, current data indicate that a number of pheromones may serendipitously exert effects on multiple species, and so this additional classic criterion should be dropped. For example, airborne chemosignals from female hamsters affect ovarian function in rats (Weizenbaum et al., 1977) . Thus, the fact that androstadienone has specific effects on humans does not preclude that possibility that it may play a part in sow's pheromonal responses to boars along with androstenol, particularly because it shares a metabolic pathway.
In sum, our findings provide additional evidence that androstadienone may be a human pheromone. Nonetheless, it still needs to be determined whether its psychological effects play a role in human social behavior in the context of everyday life. If it does not function under normal, nonexperimental social conditions, then it is not a pheromone.
If so, what do we call the effects of androstadienone when it is presented in nanomolar quantities? In this miniscule amount, that which is contained in 1/10th of a drop of sweat, it cannot be called or classified as a social odor because subjects were unable to perceive it as a smell or odor, either unmasked or masked, under the conditions of this and all previous experiments. It could be termed an "unconscious odor" or "a low concentration odorant of which there is no conscious awareness" (Lorig et al., 1990; Lorig, 1991) . However, "unconscious odor" and "unconscious odorant" are self-contradictory terms. An odor is by definition a conscious percept in humans and so cannot also be unconscious. Thus, we use the term "vasana" as a category for the effects of chemosignals that function neither as odors nor pheromones, yet do have effects on psychological state and behavior without being consciously detected (McClintock, 2001 (McClintock, , 2002 .
How can further work determine whether androstadienone in nanomolar amounts functions as a modulatory pheromone or a social signal or is simply a vasana? One step will be to compare the reactivity of normal participants, anosmics, and individuals with specific anosmias for androstadienone or other nonandrogenic steroids (Labows and Wysocki, 1984; Pause et al., 1999) . Another will evaluate the natural dispersal of androstadienone as a chemosignal and verify its role in normal human social interactions. Whichever type of chemosignal androstadienone ultimately proves to be, this study has demonstrated uniquivocally that brief passive inhalation of androstadienone, simply from the headspace above a small surface, is sufficient exposure to produce its psychological effects.
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